FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells

Oxidative stress is thought to be involved in the mechanism of nerve cell death in Parkinson’s disease (PD). Among several toxic oxidative species, nitric oxide (NO) has been proposed as a key element on the basis of the increased density of glial cells expressing inducible nitric oxide synthase (iNOS) in the substantia nigra (SN) of patients with PD. However, the mechanism of iNOS induction in the CNS is poorly understood, especially under pathological conditions. Because cytokines and FcεRII/CD23 antigen have been implicated in the induction of iNOS in the immune system, we investigated their role in glial cells in vitro and in the SN of patients with PD and matched control subjects. We show that, in vitro, interferon-γ (IFN-γ) together with interleukin-1β (Il-1β) and tumor necrosis factor-α (TNF-α) can induce the expression of CD23 in glial cells. Ligation of CD23 with specific antibodies resulted in the induction of iNOS and the subsequent release of NO. The activation of CD23 also led to an upregulation of TNF-α production, which was dependent on NO release. In the SN of PD patients, a significant increase in the density of glial cells expressing TNF-α, Il-1β, and IFN-γ was observed. Furthermore, although CD23 was not detectable in the SN of control subjects, it was found in both astroglial and microglial cells in parkinsonian patients. Altogether, these data demonstrate the existence of a cytokine/CD23-dependent activation pathway of iNOS and of proinflammatory mediators in glial cells and their involvement in the pathophysiology of PD.

[1]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[2]  S. Moncada,et al.  Regulation by endogenous INTERLEUKIN-10 of the expression of nitric oxide synthase induced after ligation of CD23 in human macrophages. , 1998, Cytokine.

[3]  I. Campbell Structural and Functional Impact of the Transgenic Expression of Cytokines in the CNS a , 1998, Annals of the New York Academy of Sciences.

[4]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[5]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[6]  B. Hyman,et al.  MPP+Induced Substantia Nigra Degeneration Is Attenuated in nNOS Knockout Mice , 1997, Neurobiology of Disease.

[7]  Yves Agid,et al.  Differential distribution of the normal and mutated forms of huntingtin in the human brain , 1997, Annals of neurology.

[8]  A. Imperato,et al.  Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice , 1997, Neuroscience Letters.

[9]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Ignarro,et al.  Inducible Nitric-oxide Synthase and Nitric Oxide Production in Human Fetal Astrocytes and Microglia , 1997, The Journal of Biological Chemistry.

[11]  N. Ogawa,et al.  Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain , 1996, Brain Research.

[12]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[13]  P. Debré,et al.  CD23-mediated nitric oxide synthase pathway induction in human keratinocytes is inhibited by retinoic acid derivatives. , 1996, The Journal of investigative dermatology.

[14]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[16]  M. Bukrinsky,et al.  Cytokine‐stimulated astrocytes damage human neurons via a nitric oxide mechanism , 1996, Glia.

[17]  M. D. Mossalayi,et al.  Nitric oxide production by human monocytes: evidence for a role of CD23. , 1995, Immunology today.

[18]  M. Mattson,et al.  Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Debré,et al.  The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Södersten,et al.  Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.

[21]  A. Alonso,et al.  Nitric oxide synthesis in rat peritoneal macrophages is induced by IgE/DNP complexes and cyclic AMP analogues. Evidence in favor of a common signaling mechanism. , 1995, Journal of immunology.

[22]  M. Hentze,et al.  Nitric oxide signaling to iron-regulatory protein: direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Debré,et al.  Ligation of CD23 activates soluble guanylate cyclase in human monocytes via an L‐arginine–dependent mechanism , 1995, Journal of leukocyte biology.

[24]  T. Ohtsuki,et al.  Hypoxia/reoxygenation-mediated induction of astrocyte interleukin 6: a paracrine mechanism potentially enhancing neuron survival , 1994, The Journal of experimental medicine.

[25]  T. Dawson,et al.  Gases as biological messengers: nitric oxide and carbon monoxide in the brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[26]  P. Debré,et al.  Involvement of FcϵRII/CD23 and L-Arginine Dependent Pathway in IgE-Mediated Activation of Human Eosinophils , 1994 .

[27]  Y. Agid,et al.  Distribution of manganese-dependent superoxide dismutase in the human brain , 1994, Neuroscience.

[28]  P. Debré,et al.  Involvement of Fcε:RII/CD23 and L-argininedependent pathway in IgE-mediated stimulation of human monocyte functions , 1994 .

[29]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[30]  J. Drapier,et al.  Interleukin-4 stimulates cGMP production by IFN-gamma-activated human monocytes. Involvement of the nitric oxide synthase pathway. , 1994, The Journal of biological chemistry.

[31]  J. Bonnefoy,et al.  Receptors for IgE. , 1993, Current opinion in immunology.

[32]  D. Reif,et al.  Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.

[33]  A. Veronesi,et al.  Functional implication for the topographical relationship between MHC class II and the low‐affinity IgE receptor: occupancy of CD23 prevents B lymphocytes from stimulating allogeneic mixed lymphocyte responses , 1990, European journal of immunology.

[34]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Ring,et al.  Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon , 1989, The Journal of experimental medicine.

[36]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[37]  J. Banchereau,et al.  Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma. , 1988, Journal of immunology.

[38]  J. Banchereau,et al.  The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens , 1988, The Journal of experimental medicine.

[39]  J. Banchereau,et al.  Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE. , 1987, Journal of immunology.

[40]  R. Hardy,et al.  A B cell-specific differentiation antigen, CD23, is a receptor for IgE (Fc epsilon R) on lymphocytes. , 1987, Journal of immunology.

[41]  G. Delespesse,et al.  Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor. , 1987, The EMBO journal.

[42]  A. Sehon,et al.  Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry. , 1985, Immunology.

[43]  E. Hirsch,et al.  Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[44]  E. Hirsch Does oxidative stress participate in nerve cell death in Parkinson's disease? , 1993, European neurology.

[45]  P. Debré,et al.  Expression, structure, and function of the CD23 antigen. , 1991, Advances in immunology.

[46]  G. Delespesse,et al.  IgE receptors on human lymphocytes I. Identification of the molecules binding to monoclonal anti‐Fcε receptor antibodies , 1986 .